Literature DB >> 1280258

Reconstitution of lipoprotein(a) by infusion of human low density lipoprotein into transgenic mice expressing human apolipoprotein(a).

G Chiesa1, H H Hobbs, M L Koschinsky, R M Lawn, S D Maika, R E Hammer.   

Abstract

Lipoprotein(a) (Lp(a)) is an atherosclerosis-causing lipoprotein that circulates in human plasma as a complex of low density lipoprotein (LDL) and apolipoprotein(a) (apo(a)). It is not known whether apo(a) attaches to LDL within hepatocytes prior to secretion or in plasma subsequent to secretion. Here we describe the development of a line of mice expressing the human apo(a) transgene under the control of the murine transferrin promoter. The apo(a) was secreted into the plasma, but circulated free of lipoproteins. When human (h)-LDL was injected intravenously, the circulating apo(a) rapidly associated with the lipoproteins, as determined by nondenaturing gel electrophoresis. Human HDL and mouse LDL had no such effect. When h-VLDL was injected, there was a delayed association of apo(a) with the lipoprotein fraction which suggests that apo(a) preferentially associated with a metabolic product of VLDL. The complex of apo(a) with LDL formed both in vivo and in vitro was resistant to boiling in the presence of detergents and denaturants, but was resolved upon disulfide reduction. These studies suggest that apo(a) fails to associate with mouse lipoproteins due to structural differences between human and mouse LDL, and that Lp(a) formation can occur in plasma through the association of apo(a) with circulating LDL.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1280258

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  30 in total

Review 1.  Lipoprotein(a): an elusive cardiovascular risk factor.

Authors:  Lars Berglund; Rajasekhar Ramakrishnan
Journal:  Arterioscler Thromb Vasc Biol       Date:  2004-09-02       Impact factor: 8.311

2.  Circulating Lp(a):LDL complexes contain LDL molecules proportionate to Lp(a) size and bind to galectin-1: a possible route for LDL entry into cells.

Authors:  Vasantha Kalaivani; Padinjaradath Sankunni Appukuttan
Journal:  Lipids       Date:  2014-08-21       Impact factor: 1.880

3.  Fibrinogen deficiency is compatible with the development of atherosclerosis in mice.

Authors:  Q Xiao; M J Danton; D P Witte; M C Kowala; M T Valentine; J L Degen
Journal:  J Clin Invest       Date:  1998-03-01       Impact factor: 14.808

4.  Modification of apolipoprotein(a) lysine binding site reduces atherosclerosis in transgenic mice.

Authors:  N W Boonmark; X J Lou; Z J Yang; K Schwartz; J L Zhang; E M Rubin; R M Lawn
Journal:  J Clin Invest       Date:  1997-08-01       Impact factor: 14.808

5.  Knockout of the mouse apolipoprotein B gene results in embryonic lethality in homozygotes and protection against diet-induced hypercholesterolemia in heterozygotes.

Authors:  R V Farese; S L Ruland; L M Flynn; R P Stokowski; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1995-02-28       Impact factor: 11.205

6.  Mutagenesis of the human apolipoprotein B gene in a yeast artificial chromosome reveals the site of attachment for apolipoprotein(a).

Authors:  S P McCormick; J K Ng; S Taylor; L M Flynn; R E Hammer; S G Young
Journal:  Proc Natl Acad Sci U S A       Date:  1995-10-24       Impact factor: 11.205

7.  Human C-reactive protein does not promote atherosclerosis in transgenic rabbits.

Authors:  Tomonari Koike; Shuji Kitajima; Ying Yu; Kazutoshi Nishijima; Jifeng Zhang; Yukio Ozaki; Masatoshi Morimoto; Teruo Watanabe; Sucharit Bhakdi; Yujiro Asada; Y Eugene Chen; Jianglin Fan
Journal:  Circulation       Date:  2009-11-09       Impact factor: 29.690

8.  Cys4057 of apolipoprotein(a) is essential for lipoprotein(a) assembly.

Authors:  C Brunner; H G Kraft; G Utermann; H J Müller
Journal:  Proc Natl Acad Sci U S A       Date:  1993-12-15       Impact factor: 11.205

Review 9.  Lipoprotein(a) metabolism: potential sites for therapeutic targets.

Authors:  Jane Hoover-Plow; Menggui Huang
Journal:  Metabolism       Date:  2012-10-04       Impact factor: 8.694

10.  Dimyristoylphosphotidylcholine induces conformational changes in apoB that lowers lipoprotein(a).

Authors:  Yan-Ting Wang; Anne von Zychlinski; Sally P A McCormick
Journal:  J Lipid Res       Date:  2008-12-19       Impact factor: 5.922

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.